Cosmos Health prelim 9-month revenue $54.3M, up 19% YoY; Q3 record $17.4M; FY2026 outlook >$90M reaffirmed

Cosmos Health Inc.

Preliminary nine-month revenue of ~$54.3M, up 19%, or $8.7M, from $45.6M in the first nine months of 2025; figures are unaudited.
Q3 revenue ~$17.4M vs $17.1M in Q3 2025 (+2%) and $12.4M in Q3 2024 (+40%); Q1, Q2 and Q3 2026 each set a new record for that period.
Nine-month revenue roughly matches full-year 2024 revenue of $54.4M and equals 83% of record full-year 2025 revenue of $65.3M.
FY2026 revenue outlook reaffirmed at over $90M (+~38% vs 2025), with Q4 2026 expected to be the strongest quarter in company history.
Cana Laboratories' contract-manufacturing pipeline hit a record >32.7M units; CosmoFarm distributes to >1,500 pharmacies; Sky Premium Life, C-Scrub and C-Sept brands entered new markets.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.